Acceptability and willingness to pay for a hypothetical vaccine against SARS CoV-2 by the Brazilian consumer: a cross-sectional study and the implications.
-
Authors
-
-
Dias-Godói, Isabella Piassi1, 2
-
Tadeu Rocha Sarmento, Túlio3
-
Afonso Reis, Edna2, 4
-
Peres Gargano, Ludmila3, 5
-
Godman, Brian6, 7, 8, 9
-
de Assis Acurcio, Francisco3, 5
-
Alvares-Teodoro, Juliana3, 5
-
Guerra Júnior, Augusto Afonso3, 5
-
Mariano Ruas, Cristina5
-
1
College of Public Health, Institute of Health and Biological Studies, Universidade Federal do Sul e Sudeste do Pará, Marabá, Pará, Brazil.
,
(Brazil)
-
2
Researcher of the Group (Cnpq) for Epidemiological, Economic and Pharmacological Studies of Arboviruses (EEPIFARBO) - Universidade Federal Do Sul E Sudeste Do Pará; Avenida Dos Ipês, Marabá, Pará, Brazil.
,
(Brazil)
-
3
SUS Collaborating Centre for Technology Assessment and Excellence in Health, Sala 1042, Faculdade De Farmácia, Universidade Federal De Minas Gerais, Av. Presidente Antônio Carlos, 6627, Campus Pampulha, Belo Horizonte, Minas Gerais, Brazil.
,
(Brazil)
-
4
Department of Statistics, Exact Sciences Institute, Universidade Federal De Minas Gerais, Belo Horizonte, Brazil.
,
(Brazil)
-
5
Programa De Pós-Graduação Em Medicamentos E Assistência Farmacêutica, School of Pharmacy, Universidade Federal De Minas Gerais, Belo Horizonte, Brazil.
,
(Brazil)
-
6
Department of Pharmacoepidemiology, Institute of Pharmacy and Biomedical Sciences, Glasgow, UK.
-
7
Division of Clinical Pharmacology, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden.
,
(Sweden)
-
8
Health Economics Centre, Liverpool University Management School, Liverpool, UK.
-
9
School of Pharmacy, Department of Public Health and Pharmacy Management, Sefako Health Sciences University, Pretoria, South Africa.
,
(South Africa)
- Type
- Published Article
- Journal
-
Expert review of pharmacoeconomics & outcomes research
- Publication Date
-
Jan 01, 2022
- Volume
-
22
- Issue
-
1
- Pages
-
119–129
- Identifiers
-
DOI: 10.1080/14737167.2021.1931128
-
PMID: 33993823
- Source
-
Medline
- Keywords
-
- Language
-
English
- License
-
Unknown
Abstract
The new coronavirus pandemic has appreciably impacted morbidity and mortality, as well as having an economic impact worldwide. New vaccines are a potential way forward to reduce transmission rates and subsequent infection. In Brazil, vaccines are being distributed via the public sector; however, in the future, they will be available in the private market. Information about consumers' willingness to pay (WTP) for a hypothetical vaccine against SARS CoV-2 can help future price setting discussions. A cross-sectional study was conducted with consumers in the five regions of Brazil regarding the WTP for a hypothetical vaccine against SARS CoV-2 with a 50% efficacy. A total of 1402 individuals over 18 years of age who declared not having COVID-19 at the time of the survey were interviewed. The acceptability for this hypothetical vaccine was 80.7%. In addition, the amount of WTP by Brazilian consumers for a hypothetical SARS CoV-2 vaccine was estimated at US$ 22.18(120.00 BRL). This study can contribute to decision-making to inform potential pricing for a hypothetical SARS CoV-2 vaccine.
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
This record was last updated on 05/07/2022 and may not reflect the most current and accurate biomedical/scientific data available from NLM.
The corresponding record at NLM can be accessed at
https://www.ncbi.nlm.nih.gov/pubmed/33993823
